PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
43.33%
Net income growth above 1.5x TRVN's 2.76%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
-26.41%
Both reduce yoy D&A, with TRVN at -3.70%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
-627.56%
Negative yoy deferred tax while TRVN stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
174.63%
SBC growth well above TRVN's 24.40%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-214.26%
Negative yoy working capital usage while TRVN is 2003.39%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-295.13%
Both negative yoy AP, with TRVN at -100.06%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-30.84%
Negative yoy usage while TRVN is 100.20%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
848.72%
Well above TRVN's 48.27%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-15.17%
Negative yoy CFO while TRVN is 53.75%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
Some CapEx rise while TRVN is negative at -373.86%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while TRVN is negative at -100.00%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
100.00%
Investing outflow well above TRVN's 98.28%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-2235.51%
Both yoy lines negative, with TRVN at -1.79%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
219.76%
We slightly raise equity while TRVN is negative at -100.00%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.